Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$27.82
-2.8%
$23.55
$17.24
$28.75
$17.85B0.931.38 million shs1.48 million shs
Genmab A/S stock logo
GNMSF
Genmab A/S
$284.18
$232.82
$170.00
$284.18
$18.78B0.9267 shsN/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$18.94
+1.8%
$25.45
$15.55
$36.91
$13.82B-1.024.37 million shs6.51 million shs
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
$69.02
$60.13
$49.98
$136.76
$4.90B0.73231 shs87 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
0.00%+1.02%+21.06%+21.91%+3.30%
Genmab A/S stock logo
GNMSF
Genmab A/S
0.00%+3.52%+31.37%+26.69%+6.80%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
0.00%-27.10%-28.39%-4.25%-16.56%
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
0.00%-3.45%+25.46%-1.51%-47.71%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$27.82
-2.8%
$23.55
$17.24
$28.75
$17.85B0.931.38 million shs1.48 million shs
Genmab A/S stock logo
GNMSF
Genmab A/S
$284.18
$232.82
$170.00
$284.18
$18.78B0.9267 shsN/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$18.94
+1.8%
$25.45
$15.55
$36.91
$13.82B-1.024.37 million shs6.51 million shs
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
$69.02
$60.13
$49.98
$136.76
$4.90B0.73231 shs87 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
0.00%+1.02%+21.06%+21.91%+3.30%
Genmab A/S stock logo
GNMSF
Genmab A/S
0.00%+3.52%+31.37%+26.69%+6.80%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
0.00%-27.10%-28.39%-4.25%-16.56%
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
0.00%-3.45%+25.46%-1.51%-47.71%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
2.70
Moderate Buy$39.2541.09% Upside
Genmab A/S stock logo
GNMSF
Genmab A/S
0.00
N/AN/AN/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
2.65
Moderate Buy$33.7978.38% Upside
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
3.43
BuyN/AN/A

Current Analyst Ratings Breakdown

Latest ZLDPF, SMMT, GMAB, and GNMSF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/8/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
9/8/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$50.00
9/3/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$40.00
9/3/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$40.00
9/3/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform$40.00
9/2/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$50.00
8/27/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$44.00 ➝ $50.00
8/19/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Summit Redstone
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$21.00
8/19/2025
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
8/19/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform$40.00
8/18/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$21.00
(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$3.26B5.47$1.47 per share18.87$8.04 per share3.46
Genmab A/S stock logo
GNMSF
Genmab A/S
$3.12B6.01$15.19 per share18.71$80.53 per share3.53
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$700K20,099.40N/AN/A$0.53 per share35.74
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
$9.09M539.25N/AN/A$17.59 per share3.92
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$1.14B$1.9913.9815.631.6737.53%21.03%16.98%11/6/2025 (Estimated)
Genmab A/S stock logo
GNMSF
Genmab A/S
$1.14B$19.9214.27N/A37.53%21.03%16.98%11/6/2025 (Estimated)
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$221.32M-$1.01N/AN/AN/AN/A-208.64%-181.28%10/29/2025 (Estimated)
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
-$156.43M$14.244.85N/AN/A73.90%67.06%61.12%11/6/2025 (Estimated)

Latest ZLDPF, SMMT, GMAB, and GNMSF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
$16.72$16.06-$0.66$16.06$9.18 billion$1.43 billion
8/11/2025Q2 2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.10-$0.76-$0.66-$0.76N/AN/A
8/7/2025Q2 2025
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$0.39$0.54+$0.15$0.54$5.77 billion$925.00 million
8/7/2025Q2 2025
Genmab A/S stock logo
GNMSF
Genmab A/S
$3.99$5.42+$1.43$5.42$949.06 million$925.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
N/AN/AN/AN/AN/A
Genmab A/S stock logo
GNMSF
Genmab A/S
N/AN/AN/AN/AN/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/AN/A
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
N/A
6.22
6.20
Genmab A/S stock logo
GNMSF
Genmab A/S
N/A
6.22
6.20
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/A
5.13
5.13
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
0.02
15.09
25.07

Institutional Ownership

CompanyInstitutional Ownership
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
7.07%
Genmab A/S stock logo
GNMSF
Genmab A/S
N/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
4.61%
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
N/A

Insider Ownership

CompanyInsider Ownership
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
1.54%
Genmab A/S stock logo
GNMSF
Genmab A/S
1.54%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
84.90%
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
2,682641.59 million631.71 millionOptionable
Genmab A/S stock logo
GNMSF
Genmab A/S
2,68266.08 million65.06 millionNot Optionable
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
110742.85 million112.17 millionOptionable
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
34071.02 millionN/ANot Optionable

Recent News About These Companies

Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down - Here's Why
Deutsche Bank Remains a Hold on Zealand Pharma (ZLDPF)
William Blair Estimates OTCMKTS:ZLDPF Q3 Earnings
Zealand Pharma appoints Utpal Singh as CSO

New MarketBeat Followers Over Time

Media Sentiment Over Time

Genmab A/S stock logo

Genmab A/S NASDAQ:GMAB

$27.82 -0.79 (-2.76%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$27.82 0.00 (0.00%)
As of 09/12/2025 07:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Genmab A/S stock logo

Genmab A/S OTCMKTS:GNMSF

$284.18 0.00 (0.00%)
As of 09/12/2025

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Summit Therapeutics stock logo

Summit Therapeutics NASDAQ:SMMT

$18.94 +0.34 (+1.83%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$18.92 -0.02 (-0.11%)
As of 09/12/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Zealand Pharma A/S stock logo

Zealand Pharma A/S OTCMKTS:ZLDPF

$69.02 0.00 (0.00%)
As of 09/12/2025

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.